Alimetry, a New Zealand-based medtech startup, has successfully secured an oversubscribed US$18 million Series A2 financing round to advance the commercialization of its innovative wearable gut health monitoring device. This funding surge is propelled by the device’s growing adoption across numerous U.S. hospitals, bolstered by Alimetry’s fourth FDA clearance, the establishment of a CPT III reimbursement code, and the completion of over 30 clinical studies.
In the context of venture capital funding, Series A2 typically represents a follow-up funding round to the initial Series A financing. Companies often conduct multiple rounds within the Series A phase if they need additional funding before advancing to a Series B round. Here’s what it means in detail:
- Bridge Financing: Series A2 serves as a bridge between the original Series A round and a potential Series B, helping the company maintain momentum, scale operations, or refine its product without waiting for a full Series B round.
- Investor Confidence: An A2 round usually indicates that investors have strong confidence in the company’s progress and potential. In this case, the fact that Alimetry’s round was oversubscribed (meaning it attracted more investment interest than it could initially accommodate) shows high investor confidence in the product’s commercial viability and market demand.
- Specific Goals: Funds raised in an A2 round often support specific, immediate goals such as scaling commercialization efforts, increasing market reach, regulatory approvals, or advancing research. For Alimetry, this A2 funding is focused on commercializing its gut health monitoring device, especially within U.S. hospitals.
The latest funding round was led by GD1 (Global from Day One), with significant participation from the American Gastroenterological Association (AGA) GI Opportunity Fund, Olympus Innovation Ventures, Icehouse Ventures, and existing investors.
Chronic gastrointestinal (GI) disorders affect approximately 10% of the global population, manifesting as symptoms like abdominal pain, chronic indigestion, nausea, and vomiting. Traditional diagnostic methods for these conditions are often protracted and invasive, leading to delayed treatment and diminished quality of life for patients.
Alimetry’s flagship product, Gastric Alimetry, offers a non-invasive solution by utilizing a wearable device that performs Body Surface Gastric Mapping. This technology detects the stomach’s electrical activity—signals that are about 100 times weaker than those of the heart—through the skin’s surface, akin to an ultra-high-resolution electrocardiogram (ECG). During the test, patients consume a meal while the device records gastric electrophysiology, and they concurrently log symptoms into a companion app.
The collected data is transmitted to the cloud, where advanced AI-powered algorithms analyze it, drawing from a vast repository of diverse test cases. The system then generates a comprehensive Gastric Alimetry Report, providing clinicians with objective, data-driven insights to aid in diagnosing and personalizing treatment plans for gastric disorders.
Dr. Greg O’Grady, Alimetry’s CEO and Professor of Surgery at the University of Auckland, emphasizes the device’s transformative impact:
“Alimetry was designed to introduce clarity into a field that has involved lengthy, uncertain diagnostic journeys. It gives clinicians the tools they need to quickly and correctly diagnose patients so that we can move on from trial and error—and guesswork—into clarity of care and personalized medicine.”
Vignesh Kumar, Co-Managing Partner at GD1, highlights the broader implications of Alimetry’s technology:
“Alimetry turns months or even years of testing into improved clarity and safer, more accessible, less invasive care. They’ve demonstrated the power of technology to usher in a new era of tech-enabled diagnostics—in this case, the undeniable connection of gut health to patient health.”
The AGA GI Opportunity Fund also recognizes the potential of Alimetry’s platform. Dr. Michael L. Kochman, Fund Manager and Advisor, states:
“The AGA GI Opportunity Fund is excited to support Alimetry and its breakthrough platform that will improve the patient experience by reducing both the time and cost of diagnosing GI symptoms.”
Understanding the gut-brain connection is crucial in managing gastric ailments, which can stem from various factors, including diet, disease, stress, and the gut-brain axis. Alimetry’s platform integrates physiology tracking and symptom monitoring through comprehensive questionnaires within the app, enabling clinicians to achieve precise diagnoses and tailor personalized treatments.
Since its controlled market release in 2022, Gastric Alimetry has gained traction, with over 40 hospitals and clinics worldwide adopting the device. This widespread acceptance underscores the medical community’s recognition of the device’s efficacy and the pressing need for improved diagnostic tools in gastroenterology.
Alimetry’s journey from academic research to a commercial enterprise exemplifies the successful translation of scientific innovation into practical healthcare solutions. The company’s origins trace back to the Auckland Bioengineering Institute and the Faculty of Medical & Health Sciences’ Surgical Engineering Lab, where interdisciplinary research laid the foundation for their breakthroughs in digestive health.
The recent funding will accelerate Alimetry’s expansion in the U.S. market, enabling the company to enhance its commercial presence and continue developing innovative solutions for gastrointestinal health. With a commitment to transforming gut health diagnostics, Alimetry is poised to make a significant impact on patient care worldwide.
Are you interested in how AI is changing healthcare? Subscribe to our newsletter, “PulsePoint,” for updates, insights, and trends on AI innovations in healthcare.
